CN201033178Y - Novel external artificial liver supporting and treating system - Google Patents
Novel external artificial liver supporting and treating system Download PDFInfo
- Publication number
- CN201033178Y CN201033178Y CNU2007200363180U CN200720036318U CN201033178Y CN 201033178 Y CN201033178 Y CN 201033178Y CN U2007200363180 U CNU2007200363180 U CN U2007200363180U CN 200720036318 U CN200720036318 U CN 200720036318U CN 201033178 Y CN201033178 Y CN 201033178Y
- Authority
- CN
- China
- Prior art keywords
- albumin
- dialyser
- liquid
- circulation line
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
A new in vitro artificial liver support and therapy system is provided, which comprises an in vitro blood circulation line and albumin solution circulation line. The utility model is characterized in that: the system also comprises a replacement fluid line which is composed of a replacement fluid container [8], an ultrafiltrate vessel [9] and a second dialyzer [6], wherein, an outlet [10] of a replacement fluid cavity of the second dialyzer [6] is connected with the ultrafiltrate vessel [9], while the outlet of the replacement fluid container [8] is connected inside the albumin solution circulation line or inside the blood circulation line. The utility model, by eliminating the toxin in the albumen circulation through filtration or hemodiafiltration, is able to eliminate medium molecular substances (including numerator inflammatory factors) effectively and thoroughly and improve the curative effect.
Description
Technical field
This utility model relates to a kind of armarium, be particularly related to a kind of temporary transient and alternative liver function of part, removing comprises the various toxin and the toxic metabolite of protein binding toxin and water solublity toxin, thus the external artificial liver support system of treatment hepatic insufficiency, liver failure or relevant disease.
Background technology
Hepatitis gravis/liver failure is the serious liver injury that multiple factor causes, cause that it is synthetic, function generation serious hindrance such as detoxifcation, drainage and biotransformation or lose compensatory, appearance serves as one group of clinical syndrome of main performance with disturbances of blood coagulation and jaundice, hepatic encephalopathy, ascites etc., and its mortality rate is up to 60～80%.For the present main method of the treatment of this disease internal medicine Comprehensive Treatment, artificial liver Supporting Therapy and liver transplantation are arranged.Wherein, external artificial rami hepatici is held and is meant by external machinery, physical chemistry or biological device, remove various harmful substances, replenish essential material, environment in regulating, based on liver powerful regeneration capacity is arranged, temporarily substitute the Therapeutic Method of depleted liver partial function, can create conditions or wait for that chance carries out liver transplantation for liver cell regeneration and liver function recovery.
Artificial liver support system is divided into abiotic type, biotype and combined three kinds.Abiotic type artificial liver is in wide clinical application and be proved to be and truly have certain curative effect.Abiotic type artificial liver method comprises plasmapheresis (plasma exchange, PE), hemoperfusion (hemoperfusion, HP), hemofiltration (hemofiltration, HF), hemodialysis (hemodialysis, HD), molecular adsorbent recirculation system (MARS), albumin absorption recirculating system (PARS) etc.And biotype and the combination Biotype artificial rami hepatici system of holding still are in conceptual phase at present.
In abiotic type artificial liver therapy system, comparatively advanced at present is molecular adsorbent recirculation system (MARS) and albumin absorption recirculating system (PARS), both principles are basic identical, they have the significant advantage that can remove protein binding toxin and water solublity toxin simultaneously than other abiotic type artificial liver therapy system.Albumin absorption recirculating system (PARS), concrete structure can be announced on August 30th, 2006 disclosed referring to Chinese patent, and the applying date is on June 22nd, 2005, and name is called the utility model patent of " a kind of external artificial liver support system ".Disclosing albumin absorption recirculating system in this patent scheme is to be made of extracorporeal circulation of blood pipeline, albumin circulation line and dialysis solution circulation line three road.
The disclosed albumin absorption of above-mentioned patent scheme recirculating system (PARS) is though have certain scavenging action to small molecular protein in conjunction with toxin and water solublity toxin, and it is still not good to the removing effect of middle molecule toxins (comprising inflammatory factor).And medically think at present the hepatitis gravis pathogenesis mainly be endotoxin inductive be that the hepatocyte that causes of the superpower immunoreation of core is further downright bad with the tumor necrosis factor, therefore artificial liver support system is if can more effectively remove the intravital various middle molecule inflammatory factors of patient, just can more effective blocking-up by endotaxin induction be the inflammation cascade reaction of core with the tumor necrosis factor, the constantly vicious cycle of progress of blocking-up hepatitis gravis/liver failure conditions of patients.
Summary of the invention
This utility model is the defective that overcomes the interior various middle molecule toxinses of removing patient body (molecule inflammatory factor in the comprising) poor effect of prior art existence, provide a kind of novel external artificial rami hepatici to hold therapy system, it can be in removing, small molecular protein is in conjunction with toxin and water solublity toxin the time, filtering middle molecule toxins (comprise in molecule inflammatory factor) more effectively, make albumin have bigger capacity and activity to remove to remove various protein binding toxins simultaneously, and can effectively remove various toxin in the body more comprehensively, more effective blocking-up is the inflammation cascade reaction of core with the tumor necrosis factor by endotaxin induction, the constantly vicious cycle of progress of blocking-up hepatitis gravis/liver failure conditions of patients, for more advantageous conditions is created in liver cell regeneration, improve hepatitis gravis/liver failure salvage success rate.
For achieving the above object, the technical solution adopted in the utility model is: a kind of novel external artificial rami hepatici is held therapy system, comprise extracorporeal circulation of blood pipeline and albumin liquid circulation line, the input of described extracorporeal circulation of blood pipeline is to the blood chamber and the relief valve that are serially connected with blood pump, first dialyser between outfan successively; Described albumin liquid circulation line mainly is connected into closed circuit by the albumin chamber of first dialyser, the albumin chamber and the albumin liquid pump of second dialyser; Its innovative point is:
Described therapy system also comprises the displacement liquid pipeline, comprises the displacement sap cavity of ultrafiltrate vessel, displacement liquid container and second dialyser in this displacement liquid pipeline; The outlet of the displacement sap cavity of described second dialyser connects the ultrafiltrate vessel; And described displacement liquid outlet of container is connected in the albumin liquid circulation line or in the blood circulation pipeline.
Related content in the technique scheme is explained as follows:
1, in the such scheme, flowing of the displacement liquid of described displacement liquid pipeline can be because of potential energy difference or pressure differential Automatic Cycle, also can be by pump as its circulation of power drive, and reducer can be set in pipeline, guarantee: effusive displacement liquid measure equates with amount of liquid in the inflow ultrafiltrate vessel in the displacement liquid container, reach the turnover liquid measure balance, this is a prior art, can adopt to existing blood filtering machine, hemofiltration dialysis machine in similar structure.
3, in the such scheme, described displacement liquid outlet of container is also connected the inlet of the displacement sap cavity of second dialyser, constitutes dialysis filtration mechanism with this, further improves the ability of removing toxin.
4, in the such scheme, this is meant that the displacement liquid outlet of container can be connected on any point or multiple spot on albumin liquid circulation line or the blood circulation pipeline described " described displacement liquid outlet of container is connected in the albumin liquid circulation line or in the blood circulation pipeline ", and wherein preferred version has following three kinds: a, described displacement liquid outlet of container are connected in the porch, albumin chamber of second dialyser in the albumin liquid circulation line; B, described displacement liquid outlet of container are connected in the exit, albumin chamber of second dialyser in the albumin liquid circulation line; C, described displacement liquid outlet of container are connected in the porch of the blood chamber of first dialyser in the blood circulation pipeline.
5, in the such scheme, also be serially connected with active carbon adsorption column, anion exchange resin adsorption column and the albuminous device of similar adsorbable regeneration in the described albumin liquid circulation line.
6, in the such scheme, also be serially connected with volume governor in the described albumin liquid circulation line, it is specially the container of a volume adjustable, the inner chamber string of this container is in albumin liquid circulation line, by adjusting the total measurement (volume) of volume governor, also reached the effect of regulating albuminous concentration in the albumin liquid circulation line with this simultaneously with regard to the whole albumin liquid of scalable circulation line.The best is that a concentration detector also is housed on the described volume governor, can show the albumin concentration in the pipeline in real time, regulates to make things convenient for medical personnel.
7, in the such scheme, in the described blood circulation pipeline, string has the transducer potector bubble trap between the blood chamber of the blood pump and first dialyser inlet, and string has vascular funnel between the blood chamber outlet of first dialyser and the relief valve.
8, in the such scheme, in the described albumin liquid circulation line, the exit in the described first dialyser albumin chamber is connected to the blood leakage monitor.
9, in the such scheme, also be serially connected with albumin liquid pipeline bubble trap in the described albumin liquid circulation line.
10, in the such scheme, described displacement liquid container exit other or that displacement liquid holds also is provided with heater, with this displacement liquid is heated, and the patient feels more comfortable when using.
11, in the such scheme, described " first dialyser " must adopt the high flux dialyser, and " second dialyser " also adopts the high flux dialyser.Described dialyser is a prior art, and it generally all has two individual cavity, separates mutually with semipermeable membrane between two cavitys.Logical blood in the cavity of first dialyser is named and is blood chamber, and logical albumin liquid in another cavity is named and is the albumin chamber.And logical albumin liquid in the cavity of second dialyser is named and is the albumin chamber, logical displacement liquid in another cavity, and naming is the displacement sap cavity.
First dialyser and second dialyser are selected with following principle:
First dialyser need guarantee in the blood in micromolecular protein binding toxin and water solublity toxin can enter the albumin circulation by its semipermeable membrane in the mode of diffusion way or convection current, and benefit materials such as cell component in the blood and high molecular weight protein can't pass through its semipermeable membrane.
Second dialyser need guarantee in the albumin liquid in micromolecular protein binding toxin and water solublity toxin can be with diffusion or convection type smoothly by its semipermeable membrane filtering, and albumin can't pass through its semipermeable membrane.
The material of the semipermeable membrane of described first dialyser and second dialyser comprises; Polysulfones, polypropylene are fine, polyamide, poly-cellulose acetate etc., and the material of film and structure need meet the following conditions: 1, have better biocompatibility, avirulence; 2, the molecular weight that dams is clear and definite, small-molecule substance can pass through smoothly in making, macromolecular substances such as protein and cell component can not pass through, preferable molecular cut off is 20000～66000Da, best molecular cut off is 50000～66000Da, generally the transmitance to protein molecular in the blood is controlled at 0.1, the best be 0.01 or below; 3, membranous wall is enough thin, and general wall thickness is 50m, and preferable wall thickness is 40m, and optimum wall thickness is 30m or thinner, has sub-permeability of high-moisture and high filtration rate, and the medium and small toxicant of various protein binding and water solublity can freely pass through; Membrane area is enough big, and general surface area is 1m
2Best area is 2m
24, be not easy attachment protein, influence filtration rate in order to avoid form coverlay; 5, physical property is stable.
12, in the such scheme, described displacement liquid gets final product for existing hemofiltration, hemofiltration dialysis displacement liquid commonly used.The composition of displacement liquid should with the outer liquid basically identical of normal human cell, absolutesterility, no pyrogenicity script simultaneously.Also can do suitable adjustment for particular patients ' according to its concrete interior ambient conditions.
Design principle of the present utility model is: this utility model is removed the water solublity toxin with the employing dialysis mode in the prior art albumin sorption cycle, be improved to and adopt filtration mode or dialysis filtration mode to remove, because of having theoretical proof now: the filtration mode is to adopt the mode of convection current to remove the water solublity toxin, and dialysis is to remove the water solublity toxin by the effect of disperse, both compare, the ability that both remove small-molecule substance is equal substantially, and to the medium molecular substance removing ability of (comprising middle molecule inflammatory factor), filtration has a clear superiority in.And dialysis filtration is dialysis and the filterable characteristics of combining, and effect is better.
Therefore, this utility model compared with prior art has following advantage:
1, simultaneously because this practicality adopts the mode of filtration or dialysis filtration that the water solublity toxin in the albumin liquid in the albumin circulation line is removed, albumin activity strengthens, absorbability improves, adsorption capacity increases, make albumin liquid can take away more protein binding toxin from blood samples of patients, a nearly step is improved therapeutic effect.
2, because this utility model adopts the mode of filtration or dialysis filtration that the water solublity toxin in the albumin liquid in the albumin circulation line is removed, medium molecular substance (molecule inflammatory factor in comprising) in the albumin liquid is removed more up hill and dale, thereby more effectively block is the inflammation cascade reaction of core with the tumor necrosis factor by endotaxin induction, the constantly vicious cycle of progress of blocking-up hepatitis gravis/liver failure conditions of patients, have immunomodulating simultaneously, improve in the patient many-sided effect such as environment, improve therapeutic effect effectively.
Description of drawings
Accompanying drawing 1 is this utility model embodiment one circulation line sketch map;
Accompanying drawing 2 is this utility model embodiment two circulation line sketch maps;
Accompanying drawing 3 is this utility model embodiment three circulation line sketch maps;
Accompanying drawing 4 is this utility model embodiment four circulation line sketch maps.
In the above accompanying drawing: 1, input; 2, outfan; 3, blood pump; 4, first dialyser; 5, relief valve; 6, second dialyser; 7, albumin liquid pump; 8, displacement liquid container; 9, ultrafiltrate vessel; 10, the outlet of second dialyser displacement sap cavity; 11, the inlet of second dialyser displacement sap cavity; 12, first dialyser blood chamber inlet; 13, first dialyser blood chamber outlet; 14, first dialyser albumin chamber inlet; 15, first dialyser albumin chamber outlet; 16, second dialyser albumin chamber inlet; 17, second dialyser albumin chamber outlet; 18, active carbon adsorption column; 19, anion exchange resin adsorption column; 20, volume governor; 21, transducer potector bubble trap; 22, vascular funnel; 23, blood leakage monitor; 24, albumin liquid pipeline bubble trap; 25, liquid feeding pump; 26, positive displacement pump.
The specific embodiment
Below in conjunction with drawings and Examples this utility model is further described:
Embodiment one: shown in accompanying drawing 1, a kind of novel external artificial rami hepatici is held therapy system, is made of extracorporeal circulation of blood pipeline, albumin liquid circulation line and displacement liquid pipeline three parts.
Shown in accompanying drawing 1, in the described extracorporeal circulation of blood pipeline, be input 1 to be connected to the blood chamber outlet 13 of blood chamber inlet 12, the first dialysers 4 of first dialyser 4 through blood pump 3, transducer potector bubble trap 21 with the artificial liver pipe special intravascular funnel 22, relief valve are connected to outfan 2 again.Blood flow in the blood chamber of described first dialyser 4 is from the top down to as shown in the figure.
Shown in accompanying drawing 1, in the described albumin liquid circulation line, be the outlet 15 in the albumin chamber of first dialyser 4 to be connected to the albumin chamber inlet 16 of second dialyser 6 successively through blood leak detector 23, albumin liquid pump 7, albumin liquid pipeline bubble trap 24, and albumin chamber outlet 17 is connected to the inlet 14 in the albumin chamber of first dialyser 4 again through volume governor 20 with the artificial liver pipe special.Above-mentionedly in albumin liquid circulation line, be connected to volume governor 20, and volume governor 20 directly has concentration detector, can adjust the overall volume of pipeline by volume adjusted actuator 20 during use, thereby reach the effect of adjusting the concentration of albumin liquid in the pipeline.Albumin liquid stream in the albumin chamber of described first dialyser 4 is from bottom to top through direction as shown in the figure, and this can guarantee optimum efficiency.
Shown in accompanying drawing 1, described displacement liquid pipeline is by displacement sap cavity, liquid feeding pump 25 and the positive displacement pump 26 of displacement liquid container 8, ultrafiltrate vessel 9, second dialyser 6; The outlet 10 of the displacement sap cavity of described second dialyser 6 connects ultrafiltrate vessel 9 through positive displacement pump 26; 16 places and the outlet of described displacement liquid container 8 enters the mouth through the albumin chamber that liquid feeding pump 25 is connected second dialyser in the albumin liquid circulation line.During use, displacement liquid enters the albumin liquid circulation line from displacement liquid container 8 and circulates, and through second dialyser 6 with the ultrafiltration mode with in the albumin liquid, small-molecule substance is leached in the ultrafiltrate vessel 9, constitutes albumin absorption filtration system.
With liquid feeding pump 25 and positive displacement pump 26, be in the present embodiment, guarantee that the displacement liquid measure that displacement liquid container 8 infeeds equals the ultrafiltration liquid measure that system discharges in system for balance control turnover liquid measure.
In the present embodiment, can set up heater on the described displacement liquid container 8, by heater displacement liquid be heated, make displacement liquid reach the suitable temperature that human body is accepted, when making treatment, it is more comfortable that the patient feels.
First dialyser of using in the present embodiment 4 adopts the hundred special HF1200 of company dialysers, and second dialyser 6 adopts Fresenius AV600 dialyser.
The present embodiment displacement liquid is the bicarbonate displacement liquid.For realizing individualized treatment, also should adjust accordingly according to patient's concrete condition.
The basic recipe of displacement liquid:
| Composition | General content (mmol/L) | Preferable content (mmol/L) |
| K+ | 0～4 | 3.0～3.5 |
| Na+ | 138～150 | 135～140 |
| Cl- | 100.7～125 | 100～115 |
| Bicarbonate | 32～38 | 105～110 |
| Ca+ * | 1.62～3.5 | 2.0～3.0 |
| Mg+ * | 0.75～1.5 | 0.4～0.6 |
Annotate: Ca+ when * selects carbonate for use, Mg+ should replenish from another passage, in order to avoid form precipitation.
Present embodiment uses certain density albumin to constitute the albumin circulation, and albumin can be competed in conjunction with removing the intravital various protein binding toxins of patient.Separable at present protein binding toxin has bilirubin, cholic acid, Short-Chain Fatty Acids, aromatic series fatty acid, mercaptan, nitric oxide, blood ammonia, tryptophan, indole and phenols metabolite.
In the present embodiment albumen circulation in protein concentration and the circulation amount of liquid all can in very large range regulate as required, easy to operate.In general, albuminous concentration range is 1～50g/L, and preferred concentration is 4.0～40g/ml.
The preparation of albumin liquid:
Concrete grammar:, be dissolved in 500 milliliters the displacement liquid with 12 of 50 milliliters 20% human albumins.
Concrete operations are as follows during use:
1, energized; Turn on the power switch;
2, press connecting line shown in the figure;
3, use displacement liquid that blood circulation pipeline, albumin circulation line are carried out preliminary filling, aerofluxus, in advance towards the time be 15min, be 20 ℃ towards temperature in advance;
4, treatment beginning; Open the turnover path of blood, albumin circulation and displacement liquid.At first albumin liquid is connected with the displacement liquid import, albumin is all injected albumin circulation (can need as the case may be to regulate proteic volume of circulation and concentration by albumen circulation volume governor), then with the inlet of displacement liquid connection with displacement liquid, treatment beginning.It is 180ml/L that blood plasma simulation flow velocity is set, and the albumin flow velocity is 250ml/L, and displacement liquid turnover flow velocity is 50ml/L, and extracorporeal circulation of blood is provided with calparine cap, replenishes heparin in case Trostin M.
5, the single therapy time is 4～8 hours, shuts down back disconnection pipeline and is connected with patient's venous.
Embodiment two: shown in accompanying drawing 2, a kind of novel external artificial rami hepatici is held therapy system, is made of extracorporeal circulation of blood pipeline, albumin liquid circulation line and displacement liquid pipeline three parts.The difference of it and embodiment one is: described displacement liquid container 8 is not 16 places that enter the mouth, the albumin chamber that is connected in second dialyser through liquid feeding pump 25, but is connected in the albumin chamber outlet 17 of second dialyser.Other repeat no more here with embodiment one.
Embodiment three: shown in accompanying drawing 3, a kind of novel external artificial rami hepatici is held therapy system, is made of extracorporeal circulation of blood pipeline, albumin liquid circulation line and displacement liquid pipeline three parts.The difference of it and embodiment one is: described displacement liquid container 8 is not 16 places that enter the mouth, the albumin chamber that is connected in second dialyser through liquid feeding pump 25,15 places but the blood chamber that is connected in first dialyser 4 in the blood circulation pipeline enters the mouth; And, also be serially connected with active carbon adsorption column 18 and anion exchange resin adsorption column 19 successively between the albumin chamber outlet 17 of described second dialyser 6 and the volume governor 20.Carry out the toxin absorption regeneration with the albumin liquid in active carbon adsorption column 18 and 19 pairs of albumin circulation lines of anion exchange resin adsorption column, further improve toxin and remove effect.
Embodiment four: shown in accompanying drawing 4, a kind of novel external artificial rami hepatici is held therapy system, is made of extracorporeal circulation of blood pipeline, albumin liquid circulation line and displacement liquid pipeline three parts.The difference of it and embodiment one is: described displacement liquid container 8 is not 16 places that enter the mouth, the albumin chamber that is connected in second dialyser through liquid feeding pump 25, but displacement liquid container 8 is divided into two-way through liquid feeding pump 25, one the road is connected on the displacement sap cavity inlet 11 of second dialyser 6, another road is connected in the albumin circulation line in second dialyser, the 6 albumin chambeies outlet 17, make flow through the from bottom to top displacement sap cavity of second dialyser 6 of one road displacement liquid (as shown in the figure) with this, another road displacement liquid flows in the albumin circulation line and circulates with albumin, finish dialysis simultaneously and filter formation dialysis filtration system.And, also be serially connected with active carbon adsorption column 18 and anion exchange resin adsorption column 19 successively between the albumin chamber outlet 17 of described second dialyser 6 and the volume governor 20.Carry out the toxin absorption regeneration with the albumin liquid in active carbon adsorption column 18 and 19 pairs of albumin circulation lines of anion exchange resin adsorption column, further improve toxin and remove effect.
The foregoing description only is explanation technical conceive of the present utility model and characteristics, and its purpose is to allow the personage who is familiar with this technology can understand content of the present utility model and enforcement according to this, can not limit protection domain of the present utility model with this.All equivalences of being done according to this utility model spirit change or modify, and all should be encompassed within the protection domain of the present utility model.
Claims (10)
1. a novel external artificial rami hepatici is held therapy system, comprise extracorporeal circulation of blood pipeline and albumin liquid circulation line, the input of described extracorporeal circulation of blood pipeline [1] is to blood chamber that is serially connected with blood pump [3], first dialyser [4] between outfan [2] successively and relief valve [5]; Described albumin liquid circulation line mainly is connected into closed circuit by the albumin chamber of first dialyser [4], the albumin chamber and the albumin liquid pump [7] of second dialyser [6]; It is characterized in that:
Described therapy system also comprises the displacement liquid pipeline, comprises the displacement sap cavity of ultrafiltrate vessel [9], displacement liquid container [8] and second dialyser [6] in this displacement liquid pipeline; The outlet [10] of the displacement sap cavity of described second dialyser [6] connects ultrafiltrate vessel [9]; And the outlet of described displacement liquid container [8] is connected in the albumin liquid circulation line or in the blood circulation pipeline.
2. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, and it is characterized in that: the inlet [11] of the displacement sap cavity of second dialyser is also connected in the outlet of described displacement liquid container [8], constitutes dialysis filtration mechanism with this.
3. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: the outlet of described displacement liquid container [8] is connected in the albumin chamber inlet [16] of second dialyser in the albumin liquid circulation line and locates.
4. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: the outlet of described displacement liquid container [8] is connected in the albumin chamber outlet [17] of second dialyser in the albumin liquid circulation line and locates.
5. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: also be serially connected with active carbon adsorption column [18] and anion exchange resin adsorption column [19] in the described albumin liquid circulation line.
6. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: also be serially connected with volume governor [20] in the described albumin liquid circulation line, it is specially the container of a volume adjustable, and the inner chamber string of this container is in albumin liquid circulation line.
7. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: in the described blood circulation pipeline, string has transducer potector bubble trap [21] between the blood chamber inlet [12] of the blood pump [3] and first dialyser, and string has vascular funnel [22] between the blood chamber outlet [13] of first dialyser and the relief valve [5].
8. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: in the described albumin liquid circulation line, the outlet [15] in the described first dialyser albumin chamber locates to be connected to blood leakage monitor [23].
9. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: also be serially connected with albumin liquid pipeline bubble trap [24] in the described albumin liquid circulation line.
10. a kind of novel external artificial rami hepatici according to claim 1 is held therapy system, it is characterized in that: described displacement liquid container [8] exit other or displacement liquid appearance [8] also is provided with constant temperature heating device.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200363180U CN201033178Y (en) | 2007-04-05 | 2007-04-05 | Novel external artificial liver supporting and treating system |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2007200363180U CN201033178Y (en) | 2007-04-05 | 2007-04-05 | Novel external artificial liver supporting and treating system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201033178Y true CN201033178Y (en) | 2008-03-12 |
Family
ID=39194071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2007200363180U Expired - Fee Related CN201033178Y (en) | 2007-04-05 | 2007-04-05 | Novel external artificial liver supporting and treating system |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201033178Y (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102107032A (en) * | 2009-12-29 | 2011-06-29 | 重庆医科大学 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
| CN102421467A (en) * | 2009-03-13 | 2012-04-18 | 梅约医学教育与研究基金会 | Bioartificial liver |
| CN103520787A (en) * | 2012-07-06 | 2014-01-22 | 中国科学院大连化学物理研究所 | Mixed type artificial liver based on loading microcapsule reciprocating type bioreactor |
| CN104127255A (en) * | 2014-07-18 | 2014-11-05 | 深圳市职业病防治院 | Blood perfusion device for experimental animal |
| CN104225698A (en) * | 2014-09-03 | 2014-12-24 | 西安交通大学 | Hepatocyte microsphere bioartificial liver supporting system |
| CN104349802A (en) * | 2012-11-08 | 2015-02-11 | 甘布罗伦迪亚股份公司 | Albumin pump control in a MARS treatment apparatus |
| CN105597176A (en) * | 2016-01-28 | 2016-05-25 | 龚德华 | Intermittent CRRT (Continuous Renal Replacement Therapy) machine capacity balance device |
| US9650609B2 (en) | 2002-06-07 | 2017-05-16 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
| CN110314260A (en) * | 2019-04-02 | 2019-10-11 | 天津市第一中心医院 | Continue albumin dialysis adsorption cleaning system and its application in children's artificial liver |
| US20210030943A1 (en) * | 2018-02-01 | 2021-02-04 | Southern Medical University Zhujiang Hospital | Combined Bio-Artificial Liver Support System |
-
2007
- 2007-04-05 CN CNU2007200363180U patent/CN201033178Y/en not_active Expired - Fee Related
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9650609B2 (en) | 2002-06-07 | 2017-05-16 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
| CN102421467A (en) * | 2009-03-13 | 2012-04-18 | 梅约医学教育与研究基金会 | Bioartificial liver |
| US10792410B2 (en) | 2009-03-13 | 2020-10-06 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
| US10130748B2 (en) | 2009-03-13 | 2018-11-20 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
| CN102107032B (en) * | 2009-12-29 | 2014-08-27 | 重庆医科大学 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
| CN102107032A (en) * | 2009-12-29 | 2011-06-29 | 重庆医科大学 | External medicine feeding device applied in macromolecular drug of low-molecular substance in blood and application thereof |
| CN103520787B (en) * | 2012-07-06 | 2016-09-14 | 中国科学院大连化学物理研究所 | A kind of based on the hybrid artificial liver carrying microcapsule reciprocating bioreactor |
| CN103520787A (en) * | 2012-07-06 | 2014-01-22 | 中国科学院大连化学物理研究所 | Mixed type artificial liver based on loading microcapsule reciprocating type bioreactor |
| CN104349802A (en) * | 2012-11-08 | 2015-02-11 | 甘布罗伦迪亚股份公司 | Albumin pump control in a MARS treatment apparatus |
| CN104127255A (en) * | 2014-07-18 | 2014-11-05 | 深圳市职业病防治院 | Blood perfusion device for experimental animal |
| CN104127255B (en) * | 2014-07-18 | 2016-08-24 | 深圳市职业病防治院 | Hemoperfusion apparatus for laboratory animal |
| CN104225698B (en) * | 2014-09-03 | 2016-04-13 | 西安交通大学 | A kind of hepatocyte microsphere circulating biological artificial liver support system |
| CN104225698A (en) * | 2014-09-03 | 2014-12-24 | 西安交通大学 | Hepatocyte microsphere bioartificial liver supporting system |
| CN105597176A (en) * | 2016-01-28 | 2016-05-25 | 龚德华 | Intermittent CRRT (Continuous Renal Replacement Therapy) machine capacity balance device |
| US20210030943A1 (en) * | 2018-02-01 | 2021-02-04 | Southern Medical University Zhujiang Hospital | Combined Bio-Artificial Liver Support System |
| US11911552B2 (en) * | 2018-02-01 | 2024-02-27 | Southern Medical University Zhujiang Hospital | Combined bio-artificial liver support system |
| CN110314260A (en) * | 2019-04-02 | 2019-10-11 | 天津市第一中心医院 | Continue albumin dialysis adsorption cleaning system and its application in children's artificial liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN201033178Y (en) | Novel external artificial liver supporting and treating system | |
| JP4177898B2 (en) | Continuous flow-through peritoneal dialysis (CFPD) with controlled intra-abdominal pressure | |
| CA2495459C (en) | Selective plasma exchange therapy | |
| CN105120913B (en) | Sodium and buffer solution source capsule for the controlled compatible stream of modularization | |
| RU2426561C2 (en) | Methods and device for peritoneal dialysis | |
| CN105025951B (en) | For the system and method for multi-functional volume fluid control | |
| CN103263704B (en) | Be equipped with the plasmapheresis absorption filtration cleaning system of slurry storing bag | |
| CN201026321Y (en) | Artificial liver nephros support system | |
| GB2124511A (en) | Method and apparatus for the purification of blood | |
| EP2076297A2 (en) | Fluid-conserving cascade hemofiltration | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| CN100493633C (en) | Artificial system for supporting liver and kidney | |
| GB1601223A (en) | Method and apparatus for continuous ambulatory peritoneal dialysis | |
| CN111315424A (en) | Method for removing toxins from blood using an extracorporeal circuit comprising a combined hollow fiber filter module and polymeric sorbent | |
| CN203196047U (en) | Combined type liver extracorporal artificial purification supportive treatment system | |
| CN202078582U (en) | Combined in-vitro artificial liver support treatment system | |
| CN201026322Y (en) | Multiple organ functions support system | |
| CN203354984U (en) | Plasma exchange adsorption filtration purification system for preparing square plasma storage pond | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| CN203244631U (en) | Plasma storage bag for plasma exchange, absorbing and filtering treatment | |
| CN203280813U (en) | Plasma exchange absorption filtering purifying system provided with plasma storage bag in matched mode | |
| CN103263706A (en) | Plasma storage bag special for plasma exchange, absorption, and filtration treatment | |
| CN111249554B (en) | Biological artificial liver purification circulation unit and artificial liver support system | |
| CN203417361U (en) | Square plasma storage pool special for plasma exchange adsorption filtration treatment | |
| Annesini et al. | Artificial Kidney |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 Termination date: 20100405 |